Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Hengstschläger M[au]:

mTORC1 and mTORC2 as regulators of cell metabolism in immunity. Linke M et al. FEBS Lett. (2017)

Regulation of innate immune cell function by mTOR. Weichhart T et al. Nat Rev Immunol. (2015)

In vitro cell migration and invasion assays. Kramer N et al. Mutat Res. (2013)

Search results

Items: 1 to 50 of 195

1.

Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer.

Unterleuthner D, Neuhold P, Schwarz K, Janker L, Neuditschko B, Nivarthi H, Crncec I, Kramer N, Unger C, Hengstschläger M, Eferl R, Moriggl R, Sommergruber W, Gerner C, Dolznig H.

Angiogenesis. 2019 Oct 30. doi: 10.1007/s10456-019-09688-8. [Epub ahead of print]

PMID:
31667643
2.

Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis.

Katholnig K, Schütz B, Fritsch SD, Schörghofer D, Linke M, Sukhbaatar N, Matschinger JM, Unterleuthner D, Hirtl M, Lang M, Herac M, Spittler A, Bergthaler A, Schabbauer G, Bergmann M, Dolznig H, Hengstschläger M, Magnuson MA, Mikula M, Weichhart T.

JCI Insight. 2019 Oct 17;4(20). pii: 124164. doi: 10.1172/jci.insight.124164.

3.

Loss of SR-BI Down-Regulates MITF and Suppresses Extracellular Vesicle Release in Human Melanoma.

Kinslechner K, Schütz B, Pistek M, Rapolter P, Weitzenböck HP, Hundsberger H, Mikulits W, Grillari J, Röhrl C, Hengstschläger M, Stangl H, Mikula M.

Int J Mol Sci. 2019 Mar 1;20(5). pii: E1063. doi: 10.3390/ijms20051063.

4.

DRUGPATH - a novel bioinformatic approach identifies DNA-damage pathway as a regulator of size maintenance in human ESCs and iPSCs.

Kovacic B, Rosner M, Schlangen K, Kramer N, Hengstschläger M.

Sci Rep. 2019 Feb 13;9(1):1897. doi: 10.1038/s41598-018-37491-w.

5.

A haunted beast: Targeting STAT5BN642H in T-Cell Neoplasia.

Pham HTT, Hengstschläger M, Moriggl R.

Mol Cell Oncol. 2018 Mar 28;5(3):e1435181. doi: 10.1080/23723556.2018.1435181. eCollection 2018.

6.

Exclusion from spheroid formation identifies loss of essential cell-cell adhesion molecules in colon cancer cells.

Stadler M, Scherzer M, Walter S, Holzner S, Pudelko K, Riedl A, Unger C, Kramer N, Weil B, Neesen J, Hengstschläger M, Dolznig H.

Sci Rep. 2018 Jan 18;8(1):1151. doi: 10.1038/s41598-018-19384-0.

7.

The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone.

Eigner K, Filik Y, Mark F, Schütz B, Klambauer G, Moriggl R, Hengstschläger M, Stangl H, Mikula M, Röhrl C.

Sci Rep. 2017 Dec 13;7(1):17498. doi: 10.1038/s41598-017-17888-9.

8.

STAT5BN642H is a driver mutation for T cell neoplasia.

Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A, Kolbe T, Elabd M, Halbritter F, Pencik J, Kazemi Z, Grebien F, Hengstschläger M, Kenner L, Kubicek S, Farlik M, Bock C, Valent P, Müller M, Rülicke T, Sexl V, Moriggl R.

J Clin Invest. 2018 Jan 2;128(1):387-401. doi: 10.1172/JCI94509. Epub 2017 Dec 4.

9.

Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation.

Kinslechner K, Schörghofer D, Schütz B, Vallianou M, Wingelhofer B, Mikulits W, Röhrl C, Hengstschläger M, Moriggl R, Stangl H, Mikula M.

Mol Cancer Res. 2018 Jan;16(1):135-146. doi: 10.1158/1541-7786.MCR-17-0292. Epub 2017 Oct 3.

10.

Human stem cells alter the invasive properties of somatic cells via paracrine activation of mTORC1.

Rosner M, Pham HTT, Moriggl R, Hengstschläger M.

Nat Commun. 2017 Sep 19;8(1):595. doi: 10.1038/s41467-017-00661-x.

11.

Methylmercury Uptake into BeWo Cells Depends on LAT2-4F2hc, a System L Amino Acid Transporter.

Balthasar C, Stangl H, Widhalm R, Granitzer S, Hengstschläger M, Gundacker C.

Int J Mol Sci. 2017 Aug 8;18(8). pii: E1730. doi: 10.3390/ijms18081730.

12.

Rapamycin Maintains the Chondrocytic Phenotype and Interferes with Inflammatory Cytokine Induced Processes.

De Luna-Preitschopf A, Zwickl H, Nehrer S, Hengstschläger M, Mikula M.

Int J Mol Sci. 2017 Jul 11;18(7). pii: E1494. doi: 10.3390/ijms18071494.

13.

mTORC1 and mTORC2 as regulators of cell metabolism in immunity.

Linke M, Fritsch SD, Sukhbaatar N, Hengstschläger M, Weichhart T.

FEBS Lett. 2017 Oct;591(19):3089-3103. doi: 10.1002/1873-3468.12711. Epub 2017 Jun 23. Review.

14.

Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression.

Kramer N, Schmöllerl J, Unger C, Nivarthi H, Rudisch A, Unterleuthner D, Scherzer M, Riedl A, Artaker M, Crncec I, Lenhardt D, Schwarz T, Prieler B, Han X, Hengstschläger M, Schüler J, Eferl R, Moriggl R, Sommergruber W, Dolznig H.

Oncogene. 2017 Sep 28;36(39):5460-5472. doi: 10.1038/onc.2017.144. Epub 2017 May 29.

PMID:
28553956
15.

Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms.

Unger C, Kramer N, Unterleuthner D, Scherzer M, Burian A, Rudisch A, Stadler M, Schlederer M, Lenhardt D, Riedl A, Walter S, Wernitznig A, Kenner L, Hengstschläger M, Schüler J, Sommergruber W, Dolznig H.

Oncogene. 2017 Sep 21;36(38):5341-5355. doi: 10.1038/onc.2017.116. Epub 2017 May 22.

PMID:
28534511
16.

An Optimized 3D Coculture Assay for Preclinical Testing of Pro- and Antiangiogenic Drugs.

Unterleuthner D, Kramer N, Pudelko K, Burian A, Hengstschläger M, Dolznig H.

SLAS Discov. 2017 Jun;22(5):602-613. doi: 10.1177/2472555216686529. Epub 2017 Jan 31.

PMID:
28346097
17.

Geophagy during pregnancy: Is there a health risk for infants?

Gundacker C, Kutalek R, Glaunach R, Deweis C, Hengstschläger M, Prinz A.

Environ Res. 2017 Jul;156:145-147. doi: 10.1016/j.envres.2017.03.028. Epub 2017 Mar 27.

PMID:
28342960
18.

Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression.

Linke M, Pham HT, Katholnig K, Schnöller T, Miller A, Demel F, Schütz B, Rosner M, Kovacic B, Sukhbaatar N, Niederreiter B, Blüml S, Kuess P, Sexl V, Müller M, Mikula M, Weckwerth W, Haschemi A, Susani M, Hengstschläger M, Gambello MJ, Weichhart T.

Nat Immunol. 2017 Mar;18(3):293-302. doi: 10.1038/ni.3655. Epub 2017 Jan 16.

19.

Generation of metastatic melanoma specific antibodies by affinity purification.

Schütz B, Koppensteiner A, Schörghofer D, Kinslechner K, Timelthaler G, Eferl R, Hengstschläger M, Missbichler A, Hundsberger H, Mikula M.

Sci Rep. 2016 Nov 17;6:37253. doi: 10.1038/srep37253.

20.

Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses.

Riedl A, Schlederer M, Pudelko K, Stadler M, Walter S, Unterleuthner D, Unger C, Kramer N, Hengstschläger M, Kenner L, Pfeiffer D, Krupitza G, Dolznig H.

J Cell Sci. 2017 Jan 1;130(1):203-218. doi: 10.1242/jcs.188102. Epub 2016 Sep 23.

21.

mTOR-Mediated Regulation of Dendritic Cell Differentiation and Function.

Sukhbaatar N, Hengstschläger M, Weichhart T.

Trends Immunol. 2016 Nov;37(11):778-789. doi: 10.1016/j.it.2016.08.009. Epub 2016 Sep 7. Review.

22.

Genetics of the human placenta: implications for toxicokinetics.

Gundacker C, Neesen J, Straka E, Ellinger I, Dolznig H, Hengstschläger M.

Arch Toxicol. 2016 Nov;90(11):2563-2581. Epub 2016 Sep 6. Review.

PMID:
27600793
23.

Letter to the Editor: Human Pluripotent Stem Cells Release Oncogenic Soluble E-Cadherin.

Rosner M, Hengstschläger M.

Stem Cells. 2016 Sep;34(9):2443-6. doi: 10.1002/stem.2461. Epub 2016 Jul 27.

24.

Full biological characterization of human pluripotent stem cells will open the door to translational research.

Kramer N, Rosner M, Kovacic B, Hengstschläger M.

Arch Toxicol. 2016 Sep;90(9):2173-2186. doi: 10.1007/s00204-016-1763-2. Epub 2016 Jun 21. Review.

PMID:
27325309
25.

Rapamycin-Induced Hypoxia Inducible Factor 2A Is Essential for Chondrogenic Differentiation of Amniotic Fluid Stem Cells.

Preitschopf A, Schörghofer D, Kinslechner K, Schütz B, Zwickl H, Rosner M, Joó JG, Nehrer S, Hengstschläger M, Mikula M.

Stem Cells Transl Med. 2016 May;5(5):580-90. doi: 10.5966/sctm.2015-0262. Epub 2016 Mar 29.

26.

Mercury toxicokinetics of the healthy human term placenta involve amino acid transporters and ABC transporters.

Straka E, Ellinger I, Balthasar C, Scheinast M, Schatz J, Szattler T, Bleichert S, Saleh L, Knöfler M, Zeisler H, Hengstschläger M, Rosner M, Salzer H, Gundacker C.

Toxicology. 2016 Jan 18;340:34-42. doi: 10.1016/j.tox.2015.12.005. Epub 2015 Dec 29.

PMID:
26740192
27.

Regulation of innate immune cell function by mTOR.

Weichhart T, Hengstschläger M, Linke M.

Nat Rev Immunol. 2015 Oct;15(10):599-614. doi: 10.1038/nri3901. Review.

28.

Increased complexity in carcinomas: Analyzing and modeling the interaction of human cancer cells with their microenvironment.

Stadler M, Walter S, Walzl A, Kramer N, Unger C, Scherzer M, Unterleuthner D, Hengstschläger M, Krupitza G, Dolznig H.

Semin Cancer Biol. 2015 Dec;35:107-24. doi: 10.1016/j.semcancer.2015.08.007. Epub 2015 Aug 28. Review.

PMID:
26320002
29.

The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence.

Schörghofer D, Kinslechner K, Preitschopf A, Schütz B, Röhrl C, Hengstschläger M, Stangl H, Mikula M.

Reprod Biol Endocrinol. 2015 Aug 7;13:88. doi: 10.1186/s12958-015-0087-z.

30.

Correction: Increasing Live Birth Rate by Preimplantation Genetic Screening of Pooled Polar Bodies Using Array Comparative Genomic Hybridization.

Feichtinger M, Stopp T, Göbl C, Feichtinger E, Vaccari E, Mädel U, Laccone F, Stroh-Weigert M, Hengstschläger M, Feichtinger W, Neesen J.

PLoS One. 2015 Jul 15;10(7):e0133334. doi: 10.1371/journal.pone.0133334. eCollection 2015.

31.

eIF3 controls cell size independently of S6K1-activity.

Schipany K, Rosner M, Ionce L, Hengstschläger M, Kovacic B.

Oncotarget. 2015 Sep 15;6(27):24361-75.

32.

Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models.

Üstün S, Lassnig C, Preitschopf A, Mikula M, Müller M, Hengstschläger M, Weichhart T.

Transpl Immunol. 2015 Sep;33(1):45-50. doi: 10.1016/j.trim.2015.06.001. Epub 2015 Jun 11.

33.

Increasing live birth rate by preimplantation genetic screening of pooled polar bodies using array comparative genomic hybridization.

Feichtinger M, Stopp T, Göbl C, Feichtinger E, Vaccari E, Mädel U, Laccone F, Stroh-Weigert M, Hengstschläger M, Feichtinger W, Neesen J.

PLoS One. 2015 May 29;10(5):e0128317. doi: 10.1371/journal.pone.0128317. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0133334.

34.

Clinical impact of studying epithelial-mesenchymal plasticity in pluripotent stem cells.

Kovacic B, Rosner M, Schipany K, Ionce L, Hengstschläger M.

Eur J Clin Invest. 2015 Apr;45(4):415-22. doi: 10.1111/eci.12415. Review.

PMID:
25646864
35.

Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development.

Unger C, Kramer N, Walzl A, Scherzer M, Hengstschläger M, Dolznig H.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:50-67. doi: 10.1016/j.addr.2014.10.015. Epub 2014 Oct 23. Review.

PMID:
25453261
36.

Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.

Kopecky C, Genser B, Drechsler C, Krane V, Kaltenecker CC, Hengstschläger M, März W, Wanner C, Säemann MD, Weichhart T.

Clin J Am Soc Nephrol. 2015 Feb 6;10(2):224-31. doi: 10.2215/CJN.06560714. Epub 2014 Nov 25.

37.

Lysis gradient centrifugation: a flexible method for the isolation of nuclei from primary cells.

Katholnig K, Poglitsch M, Hengstschläger M, Weichhart T.

Methods Mol Biol. 2015;1228:15-23. doi: 10.1007/978-1-4939-1680-1_2.

PMID:
25311118
38.

mTORC1 is essential for early steps during Schwann cell differentiation of amniotic fluid stem cells and regulates lipogenic gene expression.

Preitschopf A, Li K, Schörghofer D, Kinslechner K, Schütz B, Thi Thanh Pham H, Rosner M, Joo GJ, Röhrl C, Weichhart T, Stangl H, Lubec G, Hengstschläger M, Mikula M.

PLoS One. 2014 Sep 15;9(9):e107004. doi: 10.1371/journal.pone.0107004. eCollection 2014.

39.

Reliable quantification of protein expression and cellular localization in histological sections.

Schlederer M, Mueller KM, Haybaeck J, Heider S, Huttary N, Rosner M, Hengstschläger M, Moriggl R, Dolznig H, Kenner L.

PLoS One. 2014 Jul 11;9(7):e100822. doi: 10.1371/journal.pone.0100822. eCollection 2014.

40.

A novel missense NDP mutation [p.(Cys93Arg)] with a manifesting carrier in an austrian family with Norrie disease.

Parzefall T, Lucas T, Ritter M, Ludwig M, Ramsebner R, Frohne A, Schöfer C, Hengstschläger M, Frei K.

Audiol Neurootol. 2014;19(3):203-9. doi: 10.1159/000358866. Epub 2014 Apr 30.

PMID:
24801666
41.

The Resazurin Reduction Assay Can Distinguish Cytotoxic from Cytostatic Compounds in Spheroid Screening Assays.

Walzl A, Unger C, Kramer N, Unterleuthner D, Scherzer M, Hengstschläger M, Schwanzer-Pfeiffer D, Dolznig H.

J Biomol Screen. 2014 Aug;19(7):1047-59. doi: 10.1177/1087057114532352. Epub 2014 Apr 23.

PMID:
24758920
42.

Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide production.

Fruhwürth S, Krieger S, Winter K, Rosner M, Mikula M, Weichhart T, Bittman R, Hengstschläger M, Stangl H.

Biochim Biophys Acta. 2014 Jul;1841(7):944-53. doi: 10.1016/j.bbalip.2014.03.014. Epub 2014 Apr 5.

43.

The decision on the "optimal" human pluripotent stem cell.

Rosner M, Schipany K, Hengstschläger M.

Stem Cells Transl Med. 2014 May;3(5):553-9. doi: 10.5966/sctm.2013-0194. Epub 2014 Apr 1. Review.

44.

IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction.

Rupp C, Scherzer M, Rudisch A, Unger C, Haslinger C, Schweifer N, Artaker M, Nivarthi H, Moriggl R, Hengstschläger M, Kerjaschki D, Sommergruber W, Dolznig H, Garin-Chesa P.

Oncogene. 2015 Feb 12;34(7):815-25. doi: 10.1038/onc.2014.18. Epub 2014 Mar 17.

PMID:
24632618
45.

Intercellular protein expression variability as a feature of stem cell pluripotency.

Rosner M, Hengstschläger M.

Amino Acids. 2013 Dec;45(6):1315-7. Review.

PMID:
24077670
46.

Immune responses of macrophages and dendritic cells regulated by mTOR signalling.

Katholnig K, Linke M, Pham H, Hengstschläger M, Weichhart T.

Biochem Soc Trans. 2013 Aug;41(4):927-33. doi: 10.1042/BST20130032. Review.

47.

Tuberin and p27 expression in breast cancer patients with or without BRCA germline mutations.

Dressler AC, Hudelist G, Fink-Retter A, Gschwantler-Kaulich D, Pfeiler G, Rosner M, Hengstschläger M, Singer CF.

J Cancer Res Clin Oncol. 2013 Aug;139(8):1349-55. doi: 10.1007/s00432-013-1443-z. Epub 2013 May 21.

PMID:
23689538
48.

Merging high-quality biochemical fractionation with a refined flow cytometry approach to monitor nucleocytoplasmic protein expression throughout the unperturbed mammalian cell cycle.

Rosner M, Schipany K, Hengstschläger M.

Nat Protoc. 2013 Mar;8(3):602-26. doi: 10.1038/nprot.2013.011. Epub 2013 Feb 28.

PMID:
23449254
49.

Amniotic fluid stem cells and fetal cell microchimerism.

Rosner M, Hengstschläger M.

Trends Mol Med. 2013 May;19(5):271-2. doi: 10.1016/j.molmed.2013.01.001. Epub 2013 Jan 18. Review.

PMID:
23337352
50.

p38α senses environmental stress to control innate immune responses via mechanistic target of rapamycin.

Katholnig K, Kaltenecker CC, Hayakawa H, Rosner M, Lassnig C, Zlabinger GJ, Gaestel M, Müller M, Hengstschläger M, Hörl WH, Park JM, Säemann MD, Weichhart T.

J Immunol. 2013 Feb 15;190(4):1519-27. doi: 10.4049/jimmunol.1202683. Epub 2013 Jan 11.

Supplemental Content

Loading ...
Support Center